Back to Search
FRANK BALIS, M.D.
M.D.
Pediatric Hematology & Oncology Physician
NPI: 1780803924Individual
Specialties, Licenses & Credentials
Pediatric Hematology & Oncology PhysicianPrimary
Pediatrics — Pediatric Hematology-Oncology
Code: 2080P0207X
MD437141(PA)
Research & Publications (20)
Extracellular fluid concentrations of cisplatin, carboplatin, and oxaliplatin in brain, muscle, and blood measured using microdialysis in nonhuman primates.
PMID 19662415·Cancer Chemother Pharmacol·2010
7-preclinical
Conformational heterogeneity and quasi-static self-quenching in DNA containing a fluorescent guanine analogue, 3MI or 6MI.
PMID 19610668·Biochemistry·2009
4-observational
Phase I trial and pharmacokinetic study of ixabepilone administered daily for 5 days in children and adolescents with refractory solid tumors.
PMID 19075272·J Clin Oncol·2009
3-trial
A phase I study of the P-glycoprotein antagonist tariquidar in combination with vinorelbine.
PMID 19417029·Clin Cancer Res·2009
3-trial
Pharmacokinetics of temozolomide administered in combination with O6-benzylguanine in children and adolescents with refractory solid tumors.
PMID 19430790·Cancer Chemother Pharmacol·2009
3-trial
Phase 1 trial and pharmacokinetic study of arsenic trioxide in children and adolescents with refractory or relapsed acute leukemia, including acute promyelocytic leukemia or lymphoma.
PMID 17959855·Blood·2008
3-trial
The plasma and cerebrospinal fluid pharmacokinetics of erlotinib and its active metabolite (OSI-420) after intravenous administration of erlotinib in non-human primates.
PMID 17932674·Cancer Chemother Pharmacol·2008
7-preclinical
Characteristics and outcome of pediatric patients enrolled in phase I oncology trials.
PMID 18586923·Oncologist·2008
8-other
Plasma and cerebrospinal fluid pharmacokinetics of the histone deacetylase inhibitor, belinostat (PXD101), in non-human primates.
PMID 17960383·Cancer Chemother Pharmacol·2008
7-preclinical
A phase I study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 21 days every 28 days in pediatric patients with solid tumors.
PMID 18281544·Clin Cancer Res·2008
3-trial
Phase I clinical trial of intrathecal gemcitabine in patients with neoplastic meningitis.
PMID 17909804·Cancer Chemother Pharmacol·2008
3-trial
Substitution of oral and intravenous thioguanine for mercaptopurine in a treatment regimen for children with standard risk acute lymphoblastic leukemia: a collaborative Children's Oncology Group/National Cancer Institute pilot trial (CCG-1942).
PMID 16856155·Pediatr Blood Cancer·2007
3-trial
A phase 2 trial of all-trans-retinoic acid in combination with interferon-alpha2a in children with recurrent neuroblastoma or Wilms tumor: A Pediatric Oncology Branch, NCI and Children's Oncology Group Study.
PMID 16900483·Pediatr Blood Cancer·2007
3-trial
Plasma and cerebrospinal fluid pharmacokinetics of intravenously administered ABT-751 in non-human primates.
PMID 17187251·Cancer Chemother Pharmacol·2007
7-preclinical
NF1 plexiform neurofibroma growth rate by volumetric MRI: relationship to age and body weight.
PMID 17215493·Neurology·2007
8-other
A phase 1 study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 7 days every 21 days in pediatric patients with solid tumors.
PMID 16914576·Clin Cancer Res·2006
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 3401 CIVIC CENTER BLVD, CHILDREN'S HOSPITAL OF PHILADELPHIA - HEM/ONC
PHILADELPHIA, PA 19104 - Phone
- (215) 590-3535
Quick Facts
- NPI
- 1780803924
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile